Syros Pharmaceuticals (SYRS) News Today → This AI Trade Machine Made 1,729%* (With 89% Wins) (From Prosper Trading Academy) (Ad) Free SYRS Stock Alerts $5.04 -0.06 (-1.18%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSyros Pharmaceuticals (NASDAQ:SYRS) Downgraded to Sell at StockNews.comamericanbankingnews.com - April 18 at 5:56 AMSyros Pharmaceuticals (NASDAQ:SYRS) Rating Lowered to Sell at StockNews.commarketbeat.com - April 17 at 11:13 PMSyros Pharmaceuticals Shares Rise 20% on FDA Fast-Track Designation for Tamibarotenemarketwatch.com - April 10 at 5:56 PMSyros jumps on FDA fast track tag for leukemia drugmsn.com - April 9 at 3:57 PMFast Track Designation For Syros' Tamibarotene To Treat Acute Myeloid Leukemiamarkets.businessinsider.com - April 9 at 10:45 AMSyros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpressionbusinesswire.com - April 9 at 7:00 AMSyros Pharmaceuticals (NASDAQ:SYRS) Receives Overweight Rating from Piper Sandlermarketbeat.com - April 3 at 12:14 PMSyros Pharmaceuticals, Inc. Expected to Earn Q1 2024 Earnings of ($1.20) Per Share (NASDAQ:SYRS)marketbeat.com - April 3 at 6:00 AMSyros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)businesswire.com - April 2 at 4:30 PMSyros Pharmaceuticals (NASDAQ:SYRS) Receives "Buy" Rating from HC Wainwrightmarketbeat.com - April 1 at 8:22 AMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 31.8% in Marchmarketbeat.com - March 30 at 12:39 PMSyros Pharmaceuticals, Inc. (SYRS) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 29 at 11:42 PMEarnings call: Syros Pharmaceuticals strong Q4 and full year financialsinvesting.com - March 29 at 11:42 PMSyros Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, Brookline Capital Management Forecasts (NASDAQ:SYRS)marketbeat.com - March 29 at 8:15 AMSyros Pharmaceuticals (NASDAQ:SYRS) Upgraded to Hold by StockNews.commarketbeat.com - March 28 at 11:15 PMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 28 at 12:38 PMAnalysts Issue Forecasts for Syros Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:SYRS)marketbeat.com - March 28 at 8:59 AMSyros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene Trialsmarkets.businessinsider.com - March 28 at 7:37 AMSyros Pharmaceuticals Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 28 at 7:37 AMSyros Pharmaceuticals earnings preview: what Wall Street is expectingmarkets.businessinsider.com - March 27 at 4:30 PMSYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023investorplace.com - March 27 at 12:05 PMBuy Rating Affirmed for Syros Pharmaceuticals Amidst Promising Clinical Trial Developmentsmarkets.businessinsider.com - March 27 at 9:54 AMSyros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Updatebusinesswire.com - March 27 at 7:30 AMSyros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trialfinance.yahoo.com - March 25 at 9:03 AMSyros Pharmaceuticals (SYRS) to Release Earnings on Wednesdaymarketbeat.com - March 21 at 11:26 AMSyros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024businesswire.com - March 20 at 7:00 AMSYRS Apr 2024 10.000 callfinance.yahoo.com - March 16 at 9:05 AMShort Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expands By 29.4%marketbeat.com - March 14 at 7:32 PMFibroGen appoints Deyaa Adib as Chief Medical Officermsn.com - March 11 at 10:11 AMSyros Pharmaceuticals (NASDAQ:SYRS) Share Price Crosses Below 50 Day Moving Average of $7.15marketbeat.com - March 9 at 4:53 AMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Sees Large Growth in Short Interestmarketbeat.com - March 1 at 1:38 PMSYRS Jul 2024 2.500 callfinance.yahoo.com - February 28 at 6:42 AMInvestors in Syros Pharmaceuticals (NASDAQ:SYRS) have seen respectable returns of 99% over the past yearfinance.yahoo.com - February 27 at 7:40 AMSyros to Participate in TD Cowen 44th Annual Health Care Conferencefinance.yahoo.com - February 27 at 7:40 AMSyros to Participate in TD Cowen 44th Annual Health Care Conferencebusinesswire.com - February 27 at 7:00 AMSyros Pharmaceuticals, Inc. (SYRS)finance.yahoo.com - February 23 at 8:29 PMSYRS Mar 2024 7.500 putfinance.yahoo.com - February 17 at 7:57 AMSyros Pharmaceuticals (NASDAQ:SYRS) Lowered to Sell at StockNews.commarketbeat.com - January 23 at 10:18 PMSyros Pharmaceuticals Inc.thestreet.com - January 23 at 10:12 AMAre You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choicefinance.yahoo.com - January 18 at 5:45 PMSyros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Whyfinance.yahoo.com - January 17 at 4:44 PMWall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Knowfinance.yahoo.com - January 16 at 3:11 PMWall Street Analysts Predict a 199.31% Upside in Syros Pharmaceuticals, Inc. (SYRS): Here's What You Should Knowfinance.yahoo.com - January 16 at 3:11 PMWhat Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stockfinance.yahoo.com - January 16 at 3:11 PMWhy Syros Pharmaceuticals (SYRS) Stock Might be a Great Pickfinance.yahoo.com - January 11 at 1:43 PMPositive Outlook for Syros Pharmaceuticals Backed by Strong Pipeline and Financial Healthmarkets.businessinsider.com - January 10 at 12:56 AMSyros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotenefinance.yahoo.com - January 8 at 12:03 PMQ1 2024 Earnings Forecast for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Issued By Brookline Capital Managementmarketbeat.com - January 4 at 8:20 AMSteven Cohen's Point72 Asset Management Acquires New Stake in Syros Pharmaceuticalsfinance.yahoo.com - January 4 at 2:06 AMSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Expected to Earn Q2 2024 Earnings of ($0.84) Per Sharemarketbeat.com - January 3 at 6:34 AM Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address This AI Trade Machine Made 1,729%* (With 89% Wins) (Ad)This A.I. trading software called out an options trade the other day with a nearly perfect historical win rate… And a cumulative gain of 1729%. How does it all work? Click Here To Get Your Free Copy SYRS Media Mentions By Week SYRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRS News Sentiment▼0.000.32▲Average Medical News Sentiment SYRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRS Articles This Week▼01▲SYRS Articles Average Week Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SYRE News IMAB News CRVO News IXHL News GLYC News RLMD News AMLX News RZLT News SKYE News SGMT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRS) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
